Teva Pharmaceuticals USA, Inc. is committed to providing quality Independent Medical Educational Grants, Corporate Charitable Donations and US Advocacy requests that benefit patients and healthcare providers.
Teva Pharmaceuticals USA, Inc. and its divisions and affiliated U.S. companies, including Teva CNS, Teva Oncology, Teva Respiratory, Teva Women's Health, and Teva Select Brands are committed to conducting their business in compliance with all applicable federal and state statutes and regulations.
Please be advised that in 2014 the Request Management portal will be closed to new Educational Grant requests during the month of June and the month of December.
You will have the ability to continue the reconciliation process for previously-submitted requests. Below are the planned closure dates to assist in your planning.
Teva is no longer able to accept grant proposals in Women's Health or specific to Breakthrough Pain. Regarding proposals specific to sleep/wake disorders, they must not exceed $10,000. Check back later in the year (e.g., October), as the portal may be reopened for grant proposals seeking support in these areas.
The portal will close at 5:00 pm EST on Friday May 30, 2014 and reopen at 8:00 am EST on Tuesday, July 1, 2014.
The portal will close at 5:00 pm EST on Wednesday, November 26, 2014 (before the Thanksgiving Holiday) and reopen at 8:00 am EST on Friday, January 2, 2015.
Teva now has grant funds available for the support of independent medical education activities dedicated to advancing best practices in the treatment of migraines. Educational objectives will be posted within the next few weeks.
For your awareness, Teva Pharmaceuticals has supported educational needs assessments in the areas of sleep disorders (Shift Work Disorder and Obstructive Sleep Apnea). The findings of these needs assessments have been recently published in a peer-reviewed journal.
To access the journal article reporting the findings of the two assessments characterizing the knowledge and practice gaps of the management of patients with SWD and OSA by sleep specialists and primary care physicians, use this link: http://www.aasmnet.org/jcsm/ViewAbstract.aspx?pid=28724
You may choose to include findings published in this article in future grant submissions; however, it may not serve as the only source demonstrating the need for education in these therapeutic areas.
Should you have any questions, you can reach us by calling 800-961-3604.